| Literature DB >> 27091858 |
.
Abstract
New research indicates a potential therapeutic target for castration-resistant prostate cancer: RORγ, which is abundant in the disease, can drive androgen receptor hyperactivity. Blocking RORγ with small-molecule antagonists suppresses AR and impedes tumor growth in mice bearing human prostate tumors, including a model resistant to the antiandrogen enzalutamide. ©2016 American Association for Cancer Research.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27091858 DOI： 10.1158/2159-8290.CD-NB2016-043
Source DB: PubMed Journal: Cancer Discov ISSN： 2159-8274 Impact factor: 39.397